← Issue №4/ week of Jul 26, 2026/Hepatology

Long-term follow-up, complications and outcomes of Meso-Rex bypass for extrahepatic portal vein obstruction (EHPVO): a systematic review.

From GI Signals issue №4: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology meta analysis · Jul 27, 2026 · Dig Liver Dis · IF 4.2

Long-term follow-up, complications and outcomes of Meso-Rex bypass for extrahepatic portal vein obstruction (EHPVO): a systematic review.

New evidenceportal hypertensionvariceal bleedingpediatricsystematic review
Clinical takeawayConsider Meso-Rex bypass for pediatric EHPVO patients with portal hypertension complications (GI bleeding, hypersplenism, thrombocytopenia) when standard medical therapy (NSBB, EVL) fails, given its high patency and low mortality but acknowledging thrombosis/stenosis risks and persistent portal hypertension.
What it foundMeso-Rex bypass achieved shunt patency in 87% (1229/1403) of pediatric EHPVO cases, with thrombosis in 9%, stenosis in 5%, recurrent GI bleeding in 13% (92/730), and 0.3% mortality (5 deaths, 1 MRB-related). Portal pressures decreased postoperatively but remained above 10 mmHg.
ContextConfirms MRB as a durable, effective surgical option for pediatric EHPVO, with consistent improvements in hematologic parameters and portal hypertension complications, though long-term follow-up protocols remain unstandardized.
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases, 'Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients with Liver Disease', 2021

Decision at stakechoosing a definitive treatment for pediatric extrahepatic portal vein obstruction (EHPVO)

… For concurrent portal vein thrombosis, anticoagulation decisions should be individualized based on thrombus acuity (recent vs. chronic), bleeding risk, and underlying etiology; liver transplantation is reserved for refractory complications, and HCC surveillance is not routine without cirrhosis.

From our summary of this standard, unedited — the part the paper bears on. … marks omitted text. Our wording, not the guideline's; read the source for its own text.

Our full summary of this standard

Manage portal hypertension without cirrhosis by confirming portal hypertensive features while excluding cirrhosis (liver biopsy is the gold standard), then performing a comprehensive etiology workup (drug history, MPN/thrombophilia/PNH screen, autoimmune, CVID, HIV, schistosomiasis). Treat portal hypertension complications the same as cirrhosis, variceal prophylaxis with NSBB (carvedilol preferred) or EVL, TIPS for refractory or recurrent bleeding, and address the underlying cause by discontinuing offending drugs and treating the specific etiology. For concurrent portal vein thrombosis, anticoagulation decisions should be individualized based on thrombus acuity (recent vs. chronic), bleeding risk, and underlying etiology; liver transplantation is reserved for refractory complications, and HCC surveillance is not routine without cirrhosis.

American Association for the Study of Liver Diseases, 'Vascular Liver Disorders, Portal Vein Thrombosis, and Procedural Bleeding in Patients with Liver Disease', 2021 · reviewed 2026-07-21 ↗
Riva P … Guérin F · Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver · IF 4.2 · PubMed ↗Permalink
← Read the whole of issue №4 Every paper GI Signals surfaces gets a page like this one. All issues